The ANZCTR website will be unavailable from 1-2pm (AEST) on Wednesday the 19th of June for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
A study to measure markers in the breath of patients with Chronic Obstructive Pulmonary Disease (COPD)
Scientific title
A randomized, double blind study testing the effect of indacaterol on exhaled and circulatory biomarkers of Chronic Obstructive Pulmonary Disease (COPD).
Secondary ID [1] 284596 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease 291893 0
Condition category
Condition code
Respiratory 292236 292236 0 0
Chronic obstructive pulmonary disease

Study type
Description of intervention(s) / exposure
Indacaterol 300micrograms daily for 10 days
We are not able to monitor adherence but will test changes in exhaled molecules on Indacaterol.
Indacaterol is an inhaler
Intervention code [1] 289369 0
Treatment: Drugs
Comparator / control treatment
Placebo - Inhaler with propellant alone
Healthy controls receive no treatment at all
Control group

Primary outcome [1] 292109 0
Effect of drug on volatile organic compounds. The drug will be given to the subject for 10 days. At the end of this period the patient will blow into a tube that would collect the exhaled breath. That tube will be sent for analysis to determine the number and concentration of organic compounds.
Timepoint [1] 292109 0
10 days
Secondary outcome [1] 308217 0
Improvement in lung function including FEV1. FEV1 is meaured by spirometry
Timepoint [1] 308217 0
10 days

Key inclusion criteria
The people eligible for the study are patients with 1)COPD. based on the criteria described below. 2) Healthy controls with no COPD and within the same age range as subjects with COPD.
1. GOLD Criteria for severity of COPD
a. Mild – FEV1/FVC< 70%, FEV1< 80%
b. Moderate – FEV1/FVC< 70%, FEV1 50-80%
2. COPD chronic bronchitis or Emphysema
3. Age – 50-70 years
4. males and females
Minimum age
50 Years
Maximum age
70 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Present smokers
2. Severe CCF
3. Liver, renal failure
4. Diabetes
5. On immunosuppressive drugs
6. Auto-immune conditions such RA
7. Vascular disease – Scleroderma , SLE
8. Any history of asthma
9. Exacerbations in the last 6 weeks
10. Women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding
11. Known sensitivity to study drug(s) or class of study drug(s)
12. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed. Patients would be recruited from the public. They would have a diagnosis of COPD and fulfill the inclusion and exclusion criteria. They would then be randomised to a treatment. The treatment is an inhaler. The palcebo and treatment inhaler are identical. Only COPD patients would be randomised.
Healthy volunteers would be recruited from the regular volunteers from theLung Institute of Western Australia
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
There would be simple randomisation using a randomisation table from a statistic book. The subjects would be randomly given an inhaler that may be placebo or treatment. The investigator is blinded to this.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Nil of note
Not Applicable
Type of endpoint/s
Statistical methods / analysis
We initially did a pilot study to identify differences in exhaled volatile organic compunds (VOCs) between healthy and COPD subjects. Based on the differences between healthy and COPD, the data was analysed by RM-ANOVA. The mean SD was a difference of 5 VOCs and for a desired change of at least 5 VOCS difference p = 0.05 and a power of 0.8, the group sizes will be n=25/group for an RM-ANOVA analysis (PASS, v13, NCSS, USA).

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 2461 0
Royal Perth Hospital - Perth
Recruitment hospital [2] 2462 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 8118 0
6000 - City Delivery Centre
Recruitment postcode(s) [2] 8119 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 289228 0
Commercial sector/Industry
Name [1] 289228 0
Country [1] 289228 0
Primary sponsor type
Lung Institute of Western Australia
The Lung Insititue of Western Australia
Ground Floor, E block
Sir Charles Gairdner Hospital
Verdun Street
Western Australia
Secondary sponsor category [1] 287900 0
Other Collaborative groups
Name [1] 287900 0
Address [1] 287900 0
Resources and Chemistry Precinct
Level 2, South Wing, Building 500
Corner Manning Road and Townsing Drive
Bentley WA 6102
Country [1] 287900 0

Ethics approval
Ethics application status
Ethics committee name [1] 290997 0
Royal Perth Human Ethics committee
Ethics committee address [1] 290997 0
Royal Perth Hospital
Murray Street
Ethics committee country [1] 290997 0
Date submitted for ethics approval [1] 290997 0
Approval date [1] 290997 0
Ethics approval number [1] 290997 0
EC 2012/125

Brief summary
We are investigating the effect of Indacaterol on the effect on volatile organic compounds (VOCS) in COPD from exhaled air.
VOCS would be initially sampled from healthy controls and COPD. The COPD patients would be randomised to treatment or placebo and VOCS measured. We would then determine whether there are specific VOCS in COPD that changes with treatment. Thsi would give us insights into biomarkers for this disease.
Trial website
Trial related presentations / publications
Nil at present
Public notes

Principal investigator
Name 48362 0
A/Prof Yuben Moodley
Address 48362 0
School of Medicine and Pharmacology-University of Western Asutralia
4th Floor
MRF Building
50 Murray Street
Country 48362 0
Phone 48362 0
+61 8 92240232
Fax 48362 0
+61 8 92240246
Email 48362 0
Contact person for public queries
Name 48363 0
A/Prof Yuben Moodley
Address 48363 0
School of Medicine and Pharmacology-UWA
4th Floor
MRF Building
50 Murray Street
Country 48363 0
Phone 48363 0
+61 8 92240232
Fax 48363 0
+61 8 92240246
Email 48363 0
Contact person for scientific queries
Name 48364 0
A/Prof Yuben Moodley
Address 48364 0
School of Medicine and Pharmacology
University of Western Australia
4th Floor
MRF Building
50 Murray Street
Country 48364 0
Phone 48364 0
+61 8 92240232
Fax 48364 0
+61 8 92240246
Email 48364 0

No information has been provided regarding IPD availability

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.